CompanyGraph
Cizzle Biotechnology Holdings Plc
CIZ · United Kingdom
cizzlebiotechnology.comFinancials as of FY2024 · latest on file
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $11.77M, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
8.71MGBP11.77M · vs all stocks (USD)
Revenue (TTM)
0.00GBPvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.0040xvs all stocks
52-Week Change
28.12%vs all stocks
Market Capitalization
8.71MGBP11.77M · vs all stocks (USD)
Enterprise Value
8.01MGBP10.82M · vs all stocks (USD)
Enterprise to EBITDA
-11.30xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-123.98%vs Biotechnology peers
Revenue (TTM)
0.00GBPvs all stocks (USD)
Revenue per Share (TTM)
0.00GBPUpdated Jul 28, 2026Gross Profit (TTM)
0.00GBPvs all stocks (USD)
EBITDA (TTM)
0.00GBPvs all stocks (USD)
Net Income (TTM)
-691.00KGBP-933.22K · vs all stocks (USD)
Operating Cash Flow (TTM)
-496.00KGBP-669.86K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-283.88KGBP-383.38K · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Jul 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00GBPFY2024 · Dec 31, 2024Operating Income
-796.00KGBP-1.08M · vs all stocks (USD)
Pre-tax Income
-2.19MGBPFY2024 · Dec 31, 2024Income Tax Expense
-21.00KGBPFY2024 · Dec 31, 2024Net Income
-2.17MGBPFY2024 · Dec 31, 2024EBIT
-796.00KGBPFY2024 · Dec 31, 2024EBITDA (Income Statement)
595.00KGBPFY2024 · Dec 31, 2024Research & Development
213.00KGBPFY2024 · Dec 31, 2024Selling, General & Administrative
333.00KGBPFY2024 · Dec 31, 2024EPS (Basic)
-0.0060GBPFY2024 · Dec 31, 2024EPS (Diluted)
-0.0060GBPFY2024 · Dec 31, 2024Basic Shares Outstanding
387.47MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
387.47MSharesFY2024 · Dec 31, 2024Net Income from Continuing Operations
-2.19MGBPFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00GBPFY2024 · Dec 31, 2024Operating Cash Flow
-2.02MGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
365.00KGBPFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-2.19MGBPFY2024 · Dec 31, 2024Stock-based Compensation
162.00KGBPFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
6.00KGBPFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
2.00KGBPFY2024 · Dec 31, 2024Net Financing Cash Flow
579.00KGBPFY2024 · Dec 31, 2024Shares Outstanding
396.39MSharesUpdated Jul 28, 2026Float Shares
307.23MSharesUpdated Jul 28, 2026% Held by Insiders
23.52%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash (MRQ)
116.00KGBP156.66K · vs all stocks (USD)
Total Cash per Share (MRQ)
0.00GBPUpdated Jul 28, 2026Total Debt (MRQ)
0.00GBPvs all stocks (USD)
Current Ratio (MRQ)
0.4150xvs Biotechnology peers
Book Value per Share (MRQ)
-0.0010GBPUpdated Jul 28, 2026Total Assets
492.00KGBP664.46K · vs all stocks (USD)
Total Current Assets
492.00KGBPFY2024 · Dec 31, 2024Total Liabilities
410.00KGBPFY2024 · Dec 31, 2024Total Non-current Assets
0.00GBPFY2024 · Dec 31, 2024Total Non-current Liabilities
0.00GBPFY2024 · Dec 31, 2024Total Current Liabilities
410.00KGBPFY2024 · Dec 31, 2024Cash
365.00KGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents
365.00KGBPFY2024 · Dec 31, 2024Other Short-term Investments
22.00KGBPFY2024 · Dec 31, 2024Inventory
2.00KGBPFY2024 · Dec 31, 2024Accounts Payable
13.00KGBPFY2024 · Dec 31, 2024Common Stock (Book)
40.00KGBPFY2024 · Dec 31, 2024Retained Earnings
-10.04MGBPFY2024 · Dec 31, 2024Total Shareholders' Equity
82.00KGBP110.74K · vs all stocks (USD)
52-Week Low
1.20GBXUpdated Jul 28, 202652-Week High
3.90GBXUpdated Jul 28, 202652-Week Change
28.12%vs all stocks
Beta
-0.0040xvs all stocks
50-Day MA
2.63GBXUpdated Jul 28, 2026200-Day MA
2.01GBXUpdated Jul 28, 2026Avg 10-Day Volume
2.51MSharesUpdated Jul 28, 2026Avg 30-Day Volume
2.95MSharesUpdated Jul 28, 2026Diluted EPS (TTM)
-0.0017GBPUpdated Jul 28, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $11.77M, lower than 95% of all stocks globallySignificant
Market cap (USD): 11,765,473.839Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Genflow Biosciences Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
BioLineRx Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Crism Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sailong Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rua Life Sciences Plc
Tier 1ProductionApproval-Gated PipelineRule
Aptamer Group Plc
Tier 1ProductionApproval-Gated PipelineRule
Thalia Therapeutics Plc
Tier 1ProductionApproval-Gated PipelineRule
Sulzer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
XTL Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Purple Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk